SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a…
- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU -- 82% of…
Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial…
-- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 --…
NuCalm Donates One-Year Membership to their Mobile App to Help Families Heal from the Trauma of Loss and Displacement WILMINGTON,…
Genetic testing can be critical to ensuring the early diagnosis and proper treatment of serious disease for patients of all…
Strategic Funding Led by Nimbus Synergies, Backed by Merck GHI, to Accelerate AI-Powered CollaborationsVANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE…
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to…
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on…
Accomplished regulatory affairs veteran to lead company’s global regulatory strategy and drug product developmentNEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE)…